Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.

British journal of clinical pharmacology - 1 Apr 1996

Gross A S, Phillips A C, Rieutord A, Shenfield G M

Abstract excerpt

1. To determine whether dexfenfluramine is a substrate of cytochrome P450 2D6 (CYP2D6), its disposition has been studied in nine extensive (EM) and eight poor metabolizers (PM) of debrisoquine. 2. Following a 30 mg dose of dexfenfluramine hydrochloride, urine was collected in all subjects for 96 h post-dose and plasma samples were collected in 11 subjects (six EMs and five PMs). Dexfenfluramine and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cytochrome P-450 CYP2D6
Share to Cytochrome P-450 Enzyme System

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Debrisoquin

Share to Isoenzymes

Share to Mixed Function Oxygenases

Share to Phenotype

Share to Polymorphism, Genetic

Source

Open in PubMed Open full text

Identifiers

PMID: 8730977
DOI: 10.1046/j.1365-2125.1996.03178.x
PMCID: PMC2042591

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The influence of the sparteine/debrisoquine genetic polymorphism on the disposition of dexfenfluramine.PMID 8730977Read ↗

Dihydrocodeine: a new opioid substrate for the polymorphic CYP2D6 in humans.Semantic proximity Read ↗

Influence of debrisoquine phenotype and of quinidine on mexiletine disposition in man.Semantic proximity Read ↗

Role of polymorphic debrisoquin 4-hydroxylase activity in the stereoselective disposition of mexiletine in humans.Semantic proximity Read ↗

Disposition of debrisoquine in Caucasians with different CYP2D6-genotypes including those with multiple genes.Semantic proximity Read ↗

Debrisoquine/sparteine hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population.Semantic proximity Read ↗

[Genetic polymorphism in human drug metabolism].Semantic proximity Read ↗

Characterization of cytochrome P450 (CYP) 2D6 drugs as substrates of human organic cation transporters and multidrug and toxin extrusion proteins.Semantic proximity Read ↗

The metabolism of mexiletine in relation to the debrisoquine/sparteine-type polymorphism of drug oxidation.Semantic proximity Read ↗

Effect of ketoconazole on venlafaxine plasma concentrations in extensive and poor metabolisers of debrisoquine.Semantic proximity Read ↗

Haloperidol disposition is dependent on the debrisoquine hydroxylation phenotype: increased plasma levels of the reduced metabolite in poor metabolizers.Semantic proximity Read ↗

Endogenous codeine and morphine in poor and extensive metabolisers of the CYP2D6 (debrisoquine/sparteine) polymorphism.Semantic proximity Read ↗

A missense mutation in exon 6 of the CYP2D6 gene leading to a histidine 324 to proline exchange is associated with the poor metabolizer phenotype of sparteine.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.